TScan Therapeutics shares jump 10.90% intraday after major investor Lynx1 Capital boosts stake by purchasing 161,801 shares.

TScan Therapeutics surged 10.90% intraday after announcing positive updates from its Alloha™ Phase 1 trial for blood cancers at the 67th American Society of Hematology meeting. The data highlighted progress in hematologic malignancies, signaling strong clinical potential. Additionally, institutional investor Lynx1 Capital Management LP bolstered its stake by purchasing 161,801 shares, reflecting confidence in the company’s therapeutic pipeline. These developments aligned with recent analyst upgrades and prior collaborations, such as the Amgen partnership, but the immediate catalyst appears to be the trial results and institutional buying, which collectively reinforced investor optimism about TScan’s research advancements and growth prospects.